0001437749-15-005080.txt : 20150313
0001437749-15-005080.hdr.sgml : 20150313
20150313192208
ACCESSION NUMBER: 0001437749-15-005080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150312
FILED AS OF DATE: 20150313
DATE AS OF CHANGE: 20150313
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HYPERION THERAPEUTICS INC
CENTRAL INDEX KEY: 0001386858
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 611512713
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 400
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 650-745-7802
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 400
CITY: BRISBANE
STATE: CA
ZIP: 94005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nash Christine A
CENTRAL INDEX KEY: 0001554403
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35614
FILM NUMBER: 15700768
MAIL ADDRESS:
STREET 1: C/O HYPERION THERAPEUTICS, INC.
STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 400
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
rdgdoc.xml
FORM 4
X0306
4
2015-03-12
0001386858
HYPERION THERAPEUTICS INC
HPTX
0001554403
Nash Christine A
C/O HYPERION THERAPEUTICS, INC.
2000 SIERRA POINT PARKWAY, SUITE 400
BRISBANE
CA
94005
1
SVP & Chief Commercial Officer
Common Stock
2015-03-10
4
M
0
10000
4.08
A
29003
D
Common Stock
2015-03-10
4
S
0
10000
35.08
D
19003
D
Stock Option (Right to Buy)
4.08
2015-03-12
4
M
0
10000
0
D
2021-04-14
Common Stock
32709
22709
D
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 15, 2014.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions ranging in price from $35.00-35.36. The reporting person undertakes to provide Hyperion Therapeutics, any security holder of Hyperion Therapeutics or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.
The shares acquired upon exercise of portion of option exercised were fully vested and exercisable. The option began vesting on April 15, 2011, at a rate of 1/48th per month.
/s/ Sally Brammell, Attorney-in-fact
2015-03-13